Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS 3521 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ISIS 3521 | BIOLOGICAL | - |
| carboplatin | DRUG | - |
| paclitaxel | DRUG | - |
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) Stage IV OR Stage IIIB with malignant pleural or pericardial effusion At least 1 unidimensionally measurable lesion At least 10 mm by spiral CT scan OR At least 20 mm by standard techniques OR Evalu...
Top 20 of 76 competitors
ISIS 3521 is an investigational drug being studied for the treatment of lung cancer, specifically non-small cell lung cancer. It is being evaluated in combination with carboplatin and paclitaxel chemotherapy. The drug is still in clinical development and has not been approved by the FDA.
ISIS 3521 is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with lung cancer.
ISIS 3521 is in Phase 3 clinical development for the treatment of non-small cell lung cancer. It is an investigational drug, meaning it has not yet been approved for commercial use. The Phase 3 trial has been completed, but the drug remains under investigation.
ISIS 3521 has been studied in a Phase 3 clinical trial registered as NCT00017407. This trial evaluated the addition of ISIS 3521 to standard chemotherapy with carboplatin and paclitaxel in patients with non-small cell lung cancer. The trial was conducted in the United States and has been completed.
ISIS 3521 is classified as a monoclonal antibody, a type of biologic drug designed to target specific proteins involved in disease. It is being investigated for its potential role in treating non-small cell lung cancer when combined with chemotherapy agents carboplatin and paclitaxel.